K C Balaji
Overview
Explore the profile of K C Balaji including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
91
Citations
1218
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gumus K, Menendez M, Baerga C, Harmon I, Kumar S, Mete M, et al.
Comput Methods Programs Biomed
. 2024 Nov;
259:108528.
PMID: 39615194
Background And Objective: Detection of extraprostatic extension (EPE) preoperatively is of critical importance in the context of prostate cancer (PCa) management and outcomes. This study aimed to characterize the radiomic...
2.
Wei Z, Iluppangama M, Qi J, Choi J, Yu A, Gage K, et al.
Cancer Control
. 2024 Nov;
31:10732748241298539.
PMID: 39545376
Dynamic contrast enhancement (DCE) imaging is a valuable sequence of multiparametric magnetic resonance imaging (mpMRI). A DCE sequence enhances the vasculature and complements T2-weighted (T2W) and Diffusion-weighted imaging (DWI), allowing...
3.
Shukla S, Osumi T, Al-Toubat M, Serrano S, Singh P, Mietzsch M, et al.
Prostate
. 2024 Oct;
85(2):156-164.
PMID: 39428693
Background: The E-cadherin, α- and β-Catenin interaction at the cell adherens junction plays a key role in cell adhesion; alteration in the expression and function of these genes are associated...
4.
MRI-based radiomic features for identifying recurrent prostate cancer after proton radiation therapy
Gumus K, Contreras S, Al-Toubat M, Harmon I, Hernandez M, Ozdemir S, et al.
J Appl Clin Med Phys
. 2024 Feb;
:e14293.
PMID: 38409947
Purpose: Magnetic Resonance Imaging (MRI) evaluation of recurrent prostate cancer (PCa) following proton beam therapy is challenging due to radiation-induced tissue changes. This study aimed to evaluate MRI-based radiomic features...
5.
Jazayeri S, Dehghanbanadaki H, Hosseini M, Taghipour P, Bacchus M, Di Valerio E, et al.
Curr Urol
. 2023 Nov;
17(4):262-267.
PMID: 37994331
Background: Vesical Imaging-Reporting and Data System (VI-RADS) was developed as a structured reporting tool to anticipate the possibility of muscle invasion. This study is aimed to investigate the diagnostic accuracy...
6.
Al-Toubat M, Serrano S, ElShafei A, Koul K, Feibus A, Balaji K
Urol Oncol
. 2023 Oct;
41(11):455.e7-455.e15.
PMID: 37838503
Introduction And Objectives: We explored characteristic genetic mutations associated with metastatic prostate cancer (PCa) by comparing next generation sequencing (NGS) data between men with or without metastatic disease at diagnosis....
7.
Shukla S, Riveros C, Al-Toubat M, Chardon-Robles J, Osumi T, Serrano S, et al.
Cancers (Basel)
. 2023 Aug;
15(15).
PMID: 37568667
Bromodomains (BD) are epigenetic readers of histone acetylation involved in chromatin remodeling and transcriptional regulation of several genes including protooncogene cellular myelocytomatosis (c-Myc). c-Myc is difficult to target directly by...
8.
ElShafei A, Al-Toubat M, Feibus A, Koul K, Jazayeri S, Lelani N, et al.
Prostate
. 2023 Jul;
83(13):1229-1237.
PMID: 37455402
Objectives: Tobacco smoking is known to cause cancers potentially predisposed by genetic risks. We compared the frequency of gene mutations using a next generation sequencing database of smokers and nonsmokers...
9.
ElShafei A, Chalfant V, Al-Toubat M, Riveros C, Feibus A, Bazargani S, et al.
Am J Clin Exp Urol
. 2023 Jul;
11(3):249-257.
PMID: 37441445
Mental illness and brain disorders such as dementia are commonly encountered in patients with cognitive impairment in urology. In this cohort study, we assessed the prevalence and outcomes of inpatient...
10.
Bazargani S, Lall C, Gopireddy D, Liu S, Way A, Al-Toubat M, et al.
Am J Clin Exp Urol
. 2023 May;
11(2):185-193.
PMID: 37168940
Extramural venous invasion (EMVI) recognized on magnetic resonance imaging (MRI) is an unequivocal biomarker for detecting adverse outcomes in rectal cancer: however it has not yet been explored in the...